Clinical trials
First-line Treatment clinical trials
Below are recruiting first-line treatment clinical trials, each written for real people, not researchers. We’re tracking 412 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07744126RecruitingPhase 2
Combination drug therapy for head and neck cancer that has spread
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
Duarte, CaliforniaAges 18 years+ - NCT07288034RecruitingPhase 2
Immunotherapy biomarkers for advanced lung cancer
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Goodyear, ArizonaAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Anchorage, AlaskaAges 18 years+ - NCT07805954RecruitingPhase 3
New targeted pills for first-line metastatic pancreatic cancer
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
Phoenix, ArizonaAges 18 years+ - NCT04713670RecruitingPhase 4
Tested medicines to cure new H. pylori infection
This trial compares different stomach-medicine combinations to eliminate a new (first-time) H. pylori infection. It may help find the most effective treatment approach for people who have never tried eradication therapy before.
TaipeiAges 20 years+ - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT05967949Recruiting
Chidamide maintenance after PTCL first treatment
This study looks back at people with PTCL who, after their initial first treatment, received chidamide as a continuing (maintenance) therapy. It aims to understand how effective and tolerated this approach may be in real-world care.
Nanjing, JiangsuAges 18 years+ - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT05789043RecruitingPhase 3
Test of immunotherapy plus pills and chemotherapy for advanced melanoma
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
BeijingAges 18 years+ - NCT05511623RecruitingPhase 2
Tislelizumab with chemoradiotherapy for stage IIIC2 cervical cancer
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
Nanning, GuangxiAges 18–70 - NCT06026800RecruitingPhase 1
Personalized mRNA vaccine plus standard treatment for advanced digestive cancers
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.
Hangzhou, ZhejiangAges 18–75 - NCT06043973RecruitingPhase 3
Almonertinib plus anlotinib for first-line advanced lung cancer
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Jinan, ShandongAges 18–75 - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05302284RecruitingPhase 3
Testing RC48-ADC plus toripalimab for first-time urothelial cancer
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75 - NCT06211790RecruitingPhase 2
Targeted first-line treatment for advanced kidney cancer based on protein profile
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
ShanghaiAges 18–75 - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT05918094RecruitingPhase 3
Testing new chemo plan plus immunotherapy for stomach cancer
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+
Hear when a new First-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line treatment?
- Yes. Clin2 currently lists 412 recruiting first-line treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.